Search results for "Benzodiazepines"

showing 10 items of 49 documents

GABAergic System in Action: Connection to Gastrointestinal Stress-related Disorders.

2017

Background: Currently, treatment of stress-related gastrointestinal disorders, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), is mainly symptomatic since there is no drug on the market that solves effectively diverse disease symptoms and comorbid states. Thus, recently GABA receptors have been identified within gastrointestinal system and it has been recognized that among various GABAergic drugs some of them influence gastrointestinal stress-related diseases. Firstly, benzodiazepines have been investigated due to their diverse effects: neuroimmunomodulatory, relief of visceral pain and anxiolytic action. Conclusion: The present review brings findings on the exp…

0301 basic medicineStremedicine.drug_classGastrointestinal DiseasesGABAergic systemDiseasePharmacologyBioinformaticsSettore BIO/09 - FisiologiaAnxiolyticInflammatory bowel diseaseIrritable Bowel Syndrome03 medical and health sciencesBenzodiazepines0302 clinical medicineReceptors GABADrug DiscoverymedicineAnimalsHumansIrritable bowel syndromeGABAergic system ; stress ; benzodiazepines ; gastrointestinal system ; stress-related disorders ; therapygamma-Aminobutyric AcidPharmacologytherapyGastrointestinal tractbusiness.industryStress-related disordersVisceral painmedicine.diseaseInflammatory Bowel Diseases030104 developmental biologystress-related disordergastrointestinal systemGABAergic030211 gastroenterology & hepatologybenzodiazepinemedicine.symptombusinessStress PsychologicalCurrent pharmaceutical design
researchProduct

Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents

2016

Novel 1,4-benzodiazepines, endowed with a Michael acceptor moiety, were designed taking advantage of a computational prediction of their pharmacokinetic parameters. Among all the synthesized derivatives, we identified a new lead compound (i.e., 4a), bearing a vinyl ketone warhead and endowed with a promising antitrypanosomal activity against Trypanosoma brucei brucei (IC50 = 5.29 µM), coupled with a lack of cytotoxicity towards mammalian cells (TC50>100 µM).

0301 basic medicineTrypanosomaKetonePeptidomimeticPeptidomimeticStereochemistryTrypanosoma brucei bruceiClinical BiochemistryPharmaceutical ScienceTrypanosoma brucei01 natural sciencesBiochemistryCell LineBenzodiazepinesMiceStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundparasitic diseasesDrug DiscoveryAnimalsStructure–activity relationshipMoietyCytotoxicityMolecular BiologyMicrowave irradiationchemistry.chemical_classificationDose-Response Relationship DrugMolecular Structurebiology010405 organic chemistryMacrophagesOrganic Chemistrybiology.organism_classificationMichael acceptors Microwave irradiation Peptidomimetics Pharmacokinetic parameters TrypanosomaTrypanocidal Agents0104 chemical sciencesPharmacokinetic parameter030104 developmental biologychemistryMichael reactionMolecular MedicineMichael acceptorLead compoundBioorganic & Medicinal Chemistry Letters
researchProduct

Intranasal midazolam for treating acute respiratory crises in a woman with stiff person syndrome.

2020

Stiff person syndrome (SPS) is a rare neurologic disorder characterized by progressively worsening rigidity and spasms of the axial and limb muscles. Dyspnea has been recently recognized as a common symptom in SPS,1 and life-threatening respiratory crises have been occasionally reported and suspected to be responsible for sudden death in these patients.2,3 The pathophysiologic mechanisms of these respiratory manifestations remain unclear. Some authors have hypothesized that rigidity and/or spasm of the muscles of the trunk could prevent normal rib cage movements and excursion of the diaphragm.1

131040301 veterinary sciencesMidazolam116Stiff-Person Syndromerespiratory crisesSudden deathstiff person syndrome midazolam respiratory crises0403 veterinary science03 medical and health sciencesBenzodiazepines0302 clinical medicineMedicineHumansStiff syndromeRespiratory systemIntranasal midazolamintranasal midazolamClinical/Scientific NotesAdministration IntranasalRib cagebusiness.industry30304 agricultural and veterinary sciencesMiddle Agedmedicine.diseaseTrunkbody regionsDyspneaNeurologyAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessRespiratory Insufficiency030217 neurology & neurosurgeryStiff person syndromeNeurology(R) neuroimmunologyneuroinflammation
researchProduct

Solid microcrystalline dispersion films as a new strategy to improve the dissolution rate of poorly water soluble drugs: A case study using olanzapine

2016

In this study, we evaluate the dissolution rate enhancement of solid microcrystalline dispersion (SMD) films of olanzapine (OLZ) formulated with four water-soluble polymers namely poly(N-vinylpyrrolidone) (PVP), poloxamer 188 (P188), poloxamer 407 (P407) and Soluplus(®) (SLP). Prepared formulations were characterised to determine particle size, morphology, hydrogen bonding interactions, thermal characteristics as well as in vitro dissolution studies conducted under sink conditions (pH 6.8). Particle size of OLZ in all formulations ranged between 42 and 58μm. Attenuated Total Reflectance Fourier Transform Infrared spectroscopy (ATR-FTIR), Differential Scanning Calorimetry (DSC) and Hot-Stage…

3003PVPDrug CompoundingSolid microcrystalline dispersionPharmaceutical SciencePoloxamer02 engineering and technologyPolyethylene Glycol030226 pharmacology & pharmacyPolyethylene GlycolsBenzodiazepines03 medical and health sciences0302 clinical medicineDifferential scanning calorimetrymedicineParticle SizePyrrolidinoneSolubilityFourier transform infrared spectroscopyPolymerPolyvinylDissolutionPharmaceutical filmBenzodiazepineChromatographyCrystallineChemistryHydrogen BondingPoloxamer021001 nanoscience & nanotechnologyPyrrolidinonesDrug LiberationMicrocrystallineSolubilityChemical engineeringOlanzapinePoloxamer 407PolyvinylsParticle sizeCrystallization0210 nano-technologymedicine.drugInternational Journal of Pharmaceutics
researchProduct

Subchronic Effects of Olanzapine on Sleep EEG in Schizophrenic Patients with Predominantly Negative Symptoms

2004

Background It is well known that sleep disturbance is an integral symptom of schizophrenia. In recent studies, a deficit of delta sleep has been observed in schizophrenic patients. Antipsychotic drugs with serotonin (5-HT2) receptor-antagonistic properties are considered to have delta sleep promoting effects. We have investigated the effects of subchronic olanzapine treatment on sleep EEG in schizophrenic patients. Methods The effects of administration of olanzapine (15 to 20 mg) on sleep were studied for four weeks in 10 male, drug-free patients suffering from schizophrenia with predominantly negative symptoms. Conventional sleep EEG parameters were investigated at baseline and after treat…

AdultMaleOlanzapineAdolescentPolysomnographymedicine.medical_treatmentPolysomnographySeverity of Illness IndexDrug Administration ScheduleBenzodiazepinesSurveys and QuestionnairesmedicineHumansPharmacology (medical)AntipsychoticSleep disorderSleep Stagesmedicine.diagnostic_testElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseSleep in non-human animalsDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthDelta RhythmOlanzapineSchizophreniaAnesthesiaDelta RhythmSchizophreniaSchizophrenic PsychologySleep StagesPsychologyAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables

2012

The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were 174 consecutive subjects included in a first episode programme with no prior treatment with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone in a randomized, open-label, prospective clinical trial. The main outcome variable was the remission criteria developed by the Remission in Schizophrenia Working Group. Clinical variables were included in a logistic regression analysis in order to predict the remission state at 1 year. At 1 year, 31% of patients met criteria for remis…

AdultMaleOlanzapinePediatricsmedicine.medical_specialtymedicine.medical_treatmentLogistic regressionSeverity of Illness IndexTime-to-TreatmentBenzodiazepinesYoung AdultRisk FactorsmedicineHumansLongitudinal StudiesAntipsychoticPsychiatryBiological PsychiatryFirst episodeRisperidoneRemission InductionPrognosisRisperidonemedicine.diseaseClinical trialPsychiatry and Mental healthLogistic ModelsPsychotic DisordersOlanzapineSchizophreniadupSchizophreniaEducational StatusHaloperidolFemaleSchizophrenic PsychologyPsychologyAntipsychotic Agentsmedicine.drugPsychiatry Research
researchProduct

Automated Determination of Ziprasidone by HPLC With Column Switching and Spectrophotometric Detection

2005

An isocratic high-performance liquid chromatography (HPLC) method with column switching and ultraviolet (UV) detection is described for quantitative analysis of the new antipsychotic drug ziprasidone. After centrifugation of serum or plasma samples and addition of fluperlapine as internal standard, the samples were injected into the HPLC system. On-line sample clean-up was conducted on a column (10 x 4.0 mm ID) filled with silica C8 material (20-microm particle size) using 8% (vol/vol) acetonitrile in deionized water as eluent. Ziprasidone was eluted and separated on ODS Hypersil C18 material (5 microm; column size 250 x 4.6 mm ID) using acetonitrile-water-tetramethylethylendiamine (50:49.6…

AdultMaleTime FactorsSensitivity and SpecificityHigh-performance liquid chromatographyDrug Administration SchedulePiperazinesAutomationBenzodiazepinesBlood serumColumn chromatographymedicineHumansPharmacology (medical)ZiprasidoneClozapineChromatography High Pressure LiquidPharmacologyDetection limitChromatographymedicine.diagnostic_testElutionChemistryReproducibility of ResultsMiddle AgedThiazolesOlanzapineSpectrophotometryTherapeutic drug monitoringSchizophreniaFemaleDrug MonitoringQuantitative analysis (chemistry)medicine.drugTherapeutic Drug Monitoring
researchProduct

Non-fatal and fatal liver failure associated with valproic acid.

2012

Little is known about hepatotoxicity associated with valproic acid (VPA), a widely used substance in neuropsychiatry.All reported cases to the German Federal Institute for Drugs and Medical Devices between 1993 and 2009 of VPA-induced serious hepatic side effects were evaluated.A total of 132 cases of serious VPA-associated liver failure were identified. Approximately one third (34.8%) occurred under VPA monotherapy, while the majority was seen with VPA plus co-medication, most frequently antiepileptics (34.8%) and benzodiazepines (16.7%). A subgroup of 34 cases (25.8%) had a fatal outcome, the largest number reported to date. Of these, 32.4% were under VPA monotherapy and 67.6% under VPA p…

AdultMalemedicine.medical_specialtyFatal outcomeAdolescentGastroenterologyBenzodiazepinesPharmacovigilancePharmacotherapyInternal medicineGermanyPharmacovigilancemedicineHumansPharmacology (medical)ChildAgedAged 80 and overValproic Acidbusiness.industryValproic AcidLiver failureInfantGeneral MedicineMiddle AgedPsychiatry and Mental healthAnesthesiaConcomitantChild Preschoollipids (amino acids peptides and proteins)AnticonvulsantsDrug Therapy CombinationFemaleChemical and Drug Induced Liver Injurybusinessmedicine.drugPharmacopsychiatry
researchProduct

Sociodemographic characteristics of female habitual benzodiazepine consumers in the catchment area of a health care centre.

1997

Adultmedicine.medical_specialtymedicine.drug_classSubstance-Related Disorders050109 social psychologyAmbulatory Care Facilities03 medical and health sciencesBenzodiazepinesCatchment Area HealthEpidemiologymedicineHumans0501 psychology and cognitive sciencesMedical prescriptionPsychiatryAgedDemographyConsumption (economics)Aged 80 and overBenzodiazepine030505 public healthHealth care centrebusiness.industryDepressionPublic health05 social sciencesPublic Health Environmental and Occupational HealthMiddle AgedAntidepressive AgentsAnti-Anxiety AgentsSocioeconomic FactorsSpainFamily medicineFemaleCatchment area0305 other medical sciencebusinessScandinavian journal of social medicine
researchProduct

Actions of two GABAA receptor benzodiazepine-site ligands that are mediated via non-γ2-dependent modulation.

2011

The potent sedative-hypnotic zolpidem and the convulsant methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM) act primarily by binding to the benzodiazepine site of the main inhibitory neurotransmitter receptor, the pentameric γ-aminobutyric acid type A receptor (GABA(A)). This binding depends critically on the wild-type F77 residue of the GABA(A) receptor γ2 subunit. Mice with γ2 subunit F77I point mutation (γ2I77 mouse line) lose the high-affinity nanomolar binding of these ligands as well as their most robust behavioral actions at low doses. Interestingly, the γ2I77 mice offer a tool to study the actions of these substances mediated via other possible binding sites of the GABA(A…

AgonistMaleZolpidemAzidesmedicine.drug_classPyridinesConvulsantsPharmacologyLigandsGABAA-rho receptor03 medical and health scienceschemistry.chemical_compoundBenzodiazepinesMice0302 clinical medicineDMCMmedicineAnimalsHumansHypnotics and SedativesBinding site030304 developmental biologyPharmacology0303 health sciencesBenzodiazepineBinding SitesBehavior AnimalGABAA receptorBrainLigand (biochemistry)Receptors GABA-AMice Inbred C57BLZolpidemProtein SubunitsHEK293 CellschemistryAutoradiographyFemale030217 neurology & neurosurgerymedicine.drugCarbolinesProtein BindingEuropean journal of pharmacology
researchProduct